Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?

Enliven Therapeutics Ownership Summary

Enliven Therapeutics is owned by 31.33% institutional investors, 8.24% insiders, and 60.43% retail investors. Orbimed advisors is the largest institutional shareholder, holding 15.28% of ELVN shares.

ELVN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Enliven Therapeutics	31.33%	8.24%	60.43%
Sector	Healthcare Stocks	232.01%	10.74%	-142.75%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Orbimed advisors	7.96M	15.28%	$162.93M
Fmr	7.13M	13.68%	$145.93M
Commodore capital lp	4.69M	9.01%	$96.06M
Fairmount funds management	3.71M	7.12%	$75.97M
Vr adviser	3.23M	6.19%	$66.04M
Polar capital	3.10M	5.94%	$63.35M
Blackrock funding, inc. /de	3.61M	5.82%	$55.65M
Vanguard group	2.80M	4.51%	$43.15M
Novo	1.43M	2.74%	$29.20M
Blackstone	1.32M	2.53%	$27.03M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Fairmount funds management	3.71M	6.84%	$75.97M
5am venture management	772.48K	5.79%	$15.81M
Commodore capital lp	4.69M	4.69%	$96.06M
Orbimed advisors	7.96M	3.84%	$162.93M
Vr adviser	3.23M	3.72%	$66.04M
Novo	1.43M	1.88%	$29.20M
Highvista strategies	259.13K	1.30%	$5.30M
Vestal point capital, lp	1.16M	1.07%	$23.75M
Patient square capital lp	308.14K	1.02%	$4.75M
Rock springs capital management lp	686.11K	0.82%	$14.04M

Top Buyers

Holder	Shares	% Assets	Change
Soleus capital management	1.02M	0.58%	1.02M
Vestal point capital, lp	1.16M	1.07%	910.00K
Duquesne family office	947.40K	0.48%	484.40K
Novo	1.43M	1.88%	341.83K
Vanguard group	2.80M	0.00%	248.65K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-848.99K
Woodline partners lp	300.50K	0.03%	-800.16K
Vr adviser	3.23M	3.72%	-800.00K
First turn management	-	-	-783.41K
Tcg crossover management	-	-	-498.00K

New Positions

Holder	Shares	% Assets	Change	Value
Soleus capital management	1.02M	0.58%	1.02M	$15.79M
Pfm health sciences, lp	156.46K	0.25%	156.46K	$3.20M
Squarepoint ops	35.84K	0.00%	35.84K	$733.75K
Axq capital, lp	14.24K	0.05%	14.24K	$219.36K
Man group	13.37K	0.00%	13.37K	$273.70K

Sold Out

Holder	Change
Clearstead advisors	-5.00
Td capital management	-16.00
Stephens consulting	-20.00
Amundi	-23.00
Parkside financial bank & trust	-25.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	85	-36.09%	19,456,209	-67.24%	31	0.34%	42	-46.84%	34	13.33%
Sep 30, 2025	52	-57.72%	9,174,149	-84.56%	17	0.14%	34	-58.02%	10	-56.52%
Jun 30, 2025	122	0.83%	59,425,065	19.12%	114	1.14%	80	23.08%	23	-30.30%
Mar 31, 2025	14	-87.27%	19,292,189	-60.47%	38	0.38%	5	-92.19%	3	-88.00%
Dec 31, 2024	112	9.80%	49,623,714	4.06%	102	1.05%	66	11.86%	25	4.17%

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 17, 2026	Heyman Richard A.	-	Sell	$32.20K
Feb 17, 2026	Collins Helen Louise	CHIEF MEDICAL OFFICER	Sell	$1.18M
Feb 06, 2026	Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sell	$145.22K
Jan 20, 2026	Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sell	$390.28K
Jan 20, 2026	Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sell	$144.81K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	16
2025 Q4	-	11
2025 Q3	-	28
2025 Q2	-	28
2025 Q1	-	14

ELVN Ownership FAQ

Who Owns Enliven Therapeutics?

Enliven Therapeutics shareholders are primarily institutional investors at 31.33%, followed by 8.24% insiders and 60.43% retail investors. The average institutional ownership in Enliven Therapeutics's industry, Biotech Stocks , is 381.47%, which Enliven Therapeutics falls below.

Who owns the most shares of Enliven Therapeutics?

Enliven Therapeutics’s largest shareholders are Orbimed advisors (7.96M shares, 15.28%), Fmr (7.13M shares, 13.68%), and Commodore capital lp (4.69M shares, 9.01%). Together, they hold 37.96% of Enliven Therapeutics’s total shares outstanding.

Does Blackrock own Enliven Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enliven Therapeutics.

Who is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested?

Fairmount funds management is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.84% of its assets in 3.71M Enliven Therapeutics shares, valued at 75.97M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools